Home / Market News / $VRDN
benzinga Corporate Catalyst Impact 55/100 ● positive

Truist Securities Maintains Buy on Viridian Therapeutics, Raises Price Target to $39

Aug 7, 2026, 1:27 PM UTC · Primary ticker $VRDN

Truist Securities has reiterated its 'Buy' rating on Viridian Therapeutics and increased its price target from $38 to $39. This analyst action signals continued confidence in the company's prospects, potentially leading to a modest positive sentiment among investors.

Truist Securities analyst Gregory Renza has maintained a 'Buy' rating on Viridian Therapeutics (VRDN) and slightly increased the price target from $38 to $39. This action indicates that the analyst sees continued upside potential for the stock, reinforcing a positive outlook for the company. For traders, this could provide a short-term positive catalyst, as analyst upgrades and price target increases often lead to increased investor interest and buying activity. Long-term, it suggests that the analyst believes in the fundamental strength or future prospects of Viridian Therapeutics. The key opportunity for traders is to potentially capitalize on any immediate upward movement, though the modest price target increase suggests a moderate rather than dramatic impact.

$VRDN positive Analyst price target increase and 'Buy' rating maintained
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.